AgomAb Therapeutics NV (NASDAQ:AGMB) Receives $32.75 Average PT from Brokerages

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have been assigned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $32.75.

Separately, HC Wainwright started coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 target price on the stock.

AgomAb Therapeutics Price Performance

Shares of AGMB opened at $12.04 on Friday. The firm has a 50-day moving average of $11.72. AgomAb Therapeutics has a 52-week low of $8.75 and a 52-week high of $17.82.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.